Expertise in
13
conditions

Dr. Debra L. Richardson

Obstetrics and Gynecology
Ou Health Stephenson Cancer Center-Gynecologic Cancer Clinic
800 NE 10th St Ste 2100, 
Oklahoma City, OK 
Accepting New Patients
Offers Telehealth
Expertise in
13
conditions
Ou Health Stephenson Cancer Center-Gynecologic Cancer Clinic
800 NE 10th St Ste 2100, 
Oklahoma City, OK 

Overview

Debra Richardson is an Obstetrics and Gynecologist practicing medicine in Oklahoma City, Oklahoma.

Dr. Richardson is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Bladder Reconstruction.

She is actively involved in clinical research, co-authoring 72 peer reviewed articles and participating in 19 clinical trials. Dr. Richardson is currently accepting new patients.

Specialties

Obstetrics and Gynecology

Licenses

Obstetrics & Gynecology in OK

Hospital Affiliations

Duncan Regional Hospital, Inc
Norman Regional
O U Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Ou Health Stephenson Cancer Center-Gynecologic Cancer Clinic
800 NE 10th St Ste 2100, Oklahoma City, OK 73104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2026
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2026
Intervention Type: Drug, Procedure
Study Phase: Phase 1
Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer
Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Procedure, Drug, Radiation, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 1
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Procedure, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Enrollment Status: Active_not_recruiting
Publish Date: June 22, 2026
Intervention Type: Drug
Study Drugs: LY3484356, Abemaciclib, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor
Study Phase: Phase 1
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Procedure, Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 04, 2026
Intervention Type: Drug, Biological
Study Drugs: GEN-1, Carboplatin, Paclitaxel
Study Phase: Phase 1/Phase 2
A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/ Placebo After Combination Chemotherapy for Patients With Advanced or Recurrent Endometrial Cancer
A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/ Placebo After Combination Chemotherapy for Patients With Advanced or Recurrent Endometrial Cancer
Enrollment Status: Completed
Publish Date: April 13, 2026
Intervention Type: Drug
Study Phase: Phase 3
Phase 2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Niraparib as a Combinatorial Immune Priming Strategy in Subjects With Platinum Sensitive Recurrent Ovarian Cancer
Phase 2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Niraparib as a Combinatorial Immune Priming Strategy in Subjects With Platinum Sensitive Recurrent Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2026
Intervention Type: Biological, Drug
Study Phase: Phase 2
Phase II Trial of Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer (OU-SCC-STAR)
Phase II Trial of Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer (OU-SCC-STAR)
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 2
View 9 Less Clinical Trials

72 Total Publications

A phase II study of androgen receptor inhibition by darolutamide in combination with leuprolide acetate and exemestane in recurrent adult-type ovarian granulosa cell tumor.
A phase II study of androgen receptor inhibition by darolutamide in combination with leuprolide acetate and exemestane in recurrent adult-type ovarian granulosa cell tumor.
Journal: Gynecologic oncology
Published: May 08, 2026
Similar Doctors
Expertise in
15
conditions
Dr. Robert S. Mannel
Obstetrics and Gynecology
Expertise in
15
conditions
Dr. Robert S. Mannel
Obstetrics and Gynecology
Referral may be required

Ou Health Stephenson Cancer Center-Gynecologic Cancer Clinic

800 NE 10th St Ste 2100, 
Oklahoma City, OK 
 (0.1 miles away)
405-271-8707
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Mannel is an Obstetrics and Gynecologist practicing medicine in Oklahoma City, Oklahoma. He has been practicing medicine for over 44 years. Dr. Mannel is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Lymphadenectomy, and Hysterectomy. Dr. Mannel is currently accepting new patients.

Expertise in
16
conditions
Dr. Laura L. Holman
Obstetrics and Gynecology
Expertise in
16
conditions
Dr. Laura L. Holman
Obstetrics and Gynecology
Referral may be required

Ou Health Stephenson Cancer Center-Gynecologic Cancer Clinic

800 NE 10th St Ste 2100, 
Oklahoma City, OK 
 (0.1 miles away)
405-271-8707
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Laura Holman is an Obstetrics and Gynecologist practicing medicine in Oklahoma City, Oklahoma. Dr. Holman is highly rated in 16 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Hysterectomy, and Lymphadenectomy. Dr. Holman is currently accepting new patients.

Expertise in
10
conditions
Dr. Kathleen N. Moore
Obstetrics and Gynecology
Expertise in
10
conditions
Dr. Kathleen N. Moore
Obstetrics and Gynecology
Referral may be required

Ou Health Stephenson Cancer Center-Gynecologic Cancer Clinic

800 NE 10th St Ste 2100, 
Oklahoma City, OK 
 (0.1 miles away)
405-271-8707
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kathleen Moore is an Obstetrics and Gynecologist practicing medicine in Oklahoma City, Oklahoma. Dr. Moore is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, Ovarian Cancer, Testicular Yolk Sac Tumor, and Ureteroscopy. Dr. Moore is currently accepting new patients.

Frequently Asked Questions about Dr. Debra L. Richardson

How do I make an appointment with Dr. Debra L. Richardson?

You can book an appointment with Dr. Debra L. Richardson by calling their office at 405-271-8707. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Debra L. Richardson a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Debra L. Richardson is classified as an Elite expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Debra L. Richardson specialize in?

While Dr. Debra L. Richardson is a Obstetrics and Gynecology, they have specific expertise in Ovarian Cancer, Endometrial Cancer, and Ovarian Carcinosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Obstetrics and Gynecology.

Does Dr. Debra L. Richardson participate in research or clinical trials?

Yes. Dr. Debra L. Richardson has published 72 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Debra L. Richardson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Debra L. Richardson accept my insurance?

Dr. Debra L. Richardson accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 405-271-8707 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Richardson's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 10 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile